Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 224

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 224
---
 method for enriching                                Allowed  
                                                                    DIV            2015              2024              2016               2024                  pancreatic endocrine cells with specific markers               
                                                                                   62/260,669                          42024087278.8      HK40098139                                                                           
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Trademark: NUCELX

    Kadimastem’s      Country      Class      Earliest      Filing               Registration          Status       Applicant        
  Ref Client Ref                              Priority      Date                 Date                                                
                                                            Application No.      Registration No.                                    
          102648      Israel                                                                           Pending      Kadimastem Ltd.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Trademark: AstroRx

    Kadimastem’s      Country      Class      Filing               Registration          Next                  Status          Applicant        
  Ref Client Ref                              Date                 Date                  Action                                                 
                                              Application No.      Registration No.                                                             
           99994      Israel                  July 26, 2016        January 1, 2018       Renewal July 26,      Registered      Kadimastem Ltd.  
                                              286776               286776                2026                                                   
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Employees

As of December 31,
2024, Kadimastem had 10 employees, six of whom are employed on a full-time basis and four employed on a part-time basis. Five of Kadimastem’s
employees are in its research and development department and five employees are in its general and administrative department.

Israeli labor laws
principally govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing employees, determination
of severance pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and anti-discrimination
laws and other conditions of employment. Subject to certain exceptions, Israeli law generally requires severance pay upon the retirement,
death or dismissal of an employee, and requires Kadimastem and its employees to make payments to the National Insurance Institute, which
is similar to the U. S. Social Security Administration. Kadimastem employees have defined benefit pension plans that comply with
applicable Israeli legal requirements, which also include the mandatory pension payments required by applicable law